Edgemoor Investment Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-1,100
Closed -$257K – 134
2019
Q2
$257K Hold
1,100
– – 0.03% 119
2019
Q1
$260K Buy
1,100
+200
+22% +$63K 0.03% 122
2018
Q4
$271K Hold
900
– – 0.04% 113
2018
Q3
$318K Hold
900
– – 0.04% 109
2018
Q2
$261K Sell
900
-25
-3% -$7.03K 0.03% 117
2018
Q1
$253K Hold
925
– – 0.03% 125
2017
Q4
$313K Buy
925
+200
+28% +$64.2K 0.04% 115
2017
Q3
$227K Buy
+725
New +$215K 0.03% 133
2017
Q1
– Sell
-725
Closed -$206K – 125
2016
Q4
$206K Hold
725
– – 0.03% 114
2016
Q3
$227K Buy
+725
New +$215K 0.03% 114
2016
Q1
– Sell
-760
Closed -$233K – 122
2015
Q4
$233K Sell
760
-105
-12% -$30.2K 0.04% 125
2015
Q3
$252K Hold
865
– – 0.04% 127
2015
Q2
$349K Hold
865
– – 0.05% 117
2015
Q1
$365K Sell
865
-210
-20% -$82.8K 0.05% 112
2014
Q4
$365K Hold
1,075
– – 0.05% 110
2014
Q3
$356K Hold
1,075
– – 0.05% 112
2014
Q2
$339K Hold
1,075
– – 0.05% 114
2014
Q1
$329K Hold
1,075
– – 0.05% 107
2013
Q4
$301K Hold
1,075
– – 0.05% 113
2013
Q3
$259K Hold
1,075
– – 0.05% 119
2013
Q2
$231K Buy
+1,075
New +$230K 0.04% 129

Other funds holding BIIB

Edgemoor Investment Advisors's BIIB Position: Q3 2019 in Review

Edgemoor Investment Advisors sold out of Biogen (BIIB) in Q3 2019, closing a stake of 1,100 shares — an estimated $257K sold.

Edgemoor Investment Advisors first reported a position in BIIB in Q2 2013 and held it in 21 quarters. The position peaked at $365K in Q1 2015. 989 funds tracked by Wall St. Rank hold BIIB as of Q3 2019.

  • Edgemoor Investment Advisors reported no remaining Biogen position as of Q3 2019 after selling out during the quarter.
  • Edgemoor Investment Advisors sold 1,100 Biogen shares in Q3 2019, an estimated $257K.
  • Edgemoor Investment Advisors first reported a position in Biogen in Q2 2013 and held it in 21 quarters.
  • Edgemoor Investment Advisors's Biogen position peaked at $365K in Q1 2015.
  • 989 funds tracked by Wall St. Rank held Biogen as of Q3 2019.

Based on Edgemoor Investment Advisors's 13F filing for Q3 2019, filed 6 Nov 2019.